2006
DOI: 10.1016/j.cca.2006.01.011
|View full text |Cite
|
Sign up to set email alerts
|

Lower serum paraoxonase-1 activity in type 2 diabetic patients correlates with nitrated apolipoprotein A-I levels

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2007
2007
2018
2018

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 9 publications
(4 citation statements)
references
References 6 publications
0
4
0
Order By: Relevance
“…PON1 possesses the ability to hydrolyze and therefore inactivate lactones, thus converting homocysteine thiolactone back to homocysteine [120]. PON-1 activity is inhibited through nitrosylation of ApoA-1 [121], so excess synthesis of nitric oxide would disrupt its function. Suppression of PON-1's antioxidant effects would lead to enhanced superoxide production, and the increased bioavailability of homocysteine thiolactone will promote sulfate synthesis from the superoxide.…”
Section: A Proposed Role For the Atheromamentioning
confidence: 99%
“…PON1 possesses the ability to hydrolyze and therefore inactivate lactones, thus converting homocysteine thiolactone back to homocysteine [120]. PON-1 activity is inhibited through nitrosylation of ApoA-1 [121], so excess synthesis of nitric oxide would disrupt its function. Suppression of PON-1's antioxidant effects would lead to enhanced superoxide production, and the increased bioavailability of homocysteine thiolactone will promote sulfate synthesis from the superoxide.…”
Section: A Proposed Role For the Atheromamentioning
confidence: 99%
“…Along with its antioxidative and homocysteine-thiolactonase activities, PON-1 has added anti-atherogenic properties against macrophage foam cell formation [10], [11], [12], [13] Oxidation of HDL may affect their functional and atheroprotective proper-ties [4], [5,16]. PON-1 mass and activity have been shown to be decreased in cardiovascular disease, diabetes and renal failure patients [17], [18], [19].…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, lower PON1 activity and, in particular, PON1 genotypes, were found to be associated with cardiovascular diseases (Mackness et al, 2003;Ng et al, 2005) and atherosclerosis (Shih et al, 1998;Tward et al, 2002;Mackness et al, 2006b) in humans and mice. Serum PON1 activity levels were also reported to be low in type 2 diabetes mellitus (Gugliucci et al, 2006;Mackness et al, 2006a;Dullaart et al, 2008). Polymorphism in the PON2 gene is also associated with coronary heart disease and type II diabetes (Hegele et al, 1997;Sanghera et al, 1998;Leus et al, 2001).…”
Section: Introductionmentioning
confidence: 94%